天箭科技(002977.SZ):上半年預虧595.56萬元至1182.23萬元
格隆匯7月4日丨天箭科技(002977.SZ)公佈2025年半年度業績預告,2025年1月1日至2025年6月30日歸屬於上市公司股東的淨利潤虧損595.56萬元—1,182.23萬元,比上年同期下降153.30%—205.81%;扣除非經常性損益後的淨利潤虧損613.62萬元—1,218.09萬元,比上年同期下降155.13%—209.44%。
本報告期內,公司預計歸屬於上市公司股東的淨利潤出現虧損,主要系公司客戶回款流程較長,部分賬款賬齡延長,公司基於會計政策對存量應收賬款計提信用減值損失。公司訂單受相關採購計劃影響,部分項目交付延遲,導致收入確認不及預期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.